Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...